Drug Database
CT

CTC-111 (Anact C)

✓ Approved

Meiji Holdings · PROC

什么是 CTC-111?

CTC-111 是一种治疗药物,由Meiji Holdings研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Anact C
公司Meiji Holdings
分子靶点PROC
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

CTC-111 作用于 1 个分子靶点:

PROCprotein C, inactivator of coagulation factors Va and VIIIa (APC, PROC1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

CTC-111 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersThrombosis✓ Approved
Skin and subcutaneous tissue disordersPurpura fulminans✓ Approved

相关研究文献

PubMedEmerging infectious diseases2026-11-19

Detection of Mycobacterium ulcerans DNA in African Fruit Bats, Cameroon, 2024.

Tchatchouang Serges S, Meyin A Ebong Solange S, Baumy Caroline C, Robbe-Saule Marie M et al.

In 2024, we detected Mycobacterium ulcerans DNA in 2 of 46 fruit bats in Akonolinga, Cameroon, whereas 111 aquatic macroinvertebrate pools were negative for M. ulcerans. Broader longitudinal surveillance will be needed to clarify the role of fruit bats as a reservoir for M. ulcerans circulation in Cameroon and Africa.

PMID 43053304
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Atomic-Scale Unveiling of the True Active Phase of Mn Porphyrin Catalysts on Au(111) Using Electrochemical Scanning Tunneling Microscopy.

Kim Yongman Y, Jeong Jaewoo J, Na Deok Kyu DK, Jeong Yongchan Y et al.

Manganese (Mn)-based molecular complexes, inspired by the MnxCay cluster in photosystem II, have been widely investigated as biomimetic catalysts for the oxygen evolution reaction (OER). However, it remains unclear whether these molecular catalysts maintain their structural integrity under operating conditions or transform into metal oxide species that serve as the true active sites. Here, we visualize the electrochemical restructuring behavior of Mn porphyrin (MnOEP) monolayers on Au(111) using electrochemical scanning tunneling microscopy (EC-STM) in alkaline electrolyte. During repeated redox cycles, the MnOEP adlayer undergoes progressive decomposition, leading to the formation of two-dimensional MnOx nanoislands on the Au surface. We show that in situ formed metal oxides act as the active catalytic species under operating conditions and play a key role in enhancing OER activity. EC-STM images reveal that the repeated MnOEP adsorptions/redox cycles result in increased surface coverage of these activated catalysts, i.e., metal oxide islands. The catalytic activity of the activated electrode is gradually strengthened as the reconstructed MnOx islands grow horizontally and expand within the monolayer, whereas multilayer oxide growth leads to diminished activity. Specifically, the controlled monatomic-high MnOx islands achieve lower overpotential with favorable OER kinetics, showing a remarkable OER current density at 1.82 V versus the reversible hydrogen electrode and surpassing initial MnOEP-catalyzed Au electrode by up to 1.8 times. These notable findings provide molecular-level insights into the active sites of MnOx-modified Au electrodes and spur the future development of water oxidation catalysts.

PMID 43053382
阅读全文 →
PubMedEuropean journal of psychotraumatology2026-11-19

Non-pharmacological augmentation of trauma-focused psychotherapy for PTSD: a systematic review and meta-analysis.

Langhammer Till T, Mewes Lisa L, Torbecke Jonathan J, Evens Ricarda R et al.

Trauma-focused psychotherapies (TFPs) effectively treat post-traumatic stress disorder (PTSD), yet patients show variable response or discontinue treatment. Numerous augmentation strategies have been developed to address these barriers, but the field lacks a framework that extends beyond mechanistic categories as well as a meta-analytic synthesis of their effects. To develop a classification framework for non-pharmacological augmentation strategies of first-line TFP for PTSD and to meta-analytically evaluate whether these strategies improve treatment outcomes. We conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) comparing TFP augmented with a non-pharmacological intervention versus TFP alone or an active control (i.e. sham intervention or dose increase). Eight databases were searched to July 2026. Augmentation strategies were qualitatively categorised. Primary outcomes were PTSD symptom severity and response rate; dropout was a secondary outcome. Fifty RCTs met inclusion criteria. Their augmentations were categorised within a three-level framework comprising targets, mechanisms, and implementation forms. Of these, 39 trials (40 comparisons; N = 2,853) were meta-analysed and showed no significant overall effects (symptom severity: g = -0.10, p = .062; response: RR = 1.04, p = .111; dropout: RR = 0.94, p = .489). One subgroup targeting sleep disturbance showed an add-on effect. The present findings suggest that augmenting TFP with non-pharmacological interventions does not necessarily lead to incremental efficacy at the overall level, even though small benefits were observed for sleep-focused strategies. Our three-level framework provides a structured approach for conceptualising this heterogeneous field. The absence of a robust overall effect should not be mistaken for evidence that augmentation cannot be effective.

PMID 43053690
阅读全文 →
PubMedTissue & cell2026-11-18

A novel CTC-based biomarker for clinically feasible breast cancer progression prediction.

Yang Yixiao Y, Chen Dagui D, Zhang Chenxi C, Shang Fusheng F et al.

Cytokeratin (CK), the standard marker for circulating tumor cells (CTCs), often yields false negatives due to low expression. This study investigates human mammaglobin (hMAM) as an alternative biomarker to improve CTC detection accuracy in breast cancer. We synthesized EpCAM antibody-modified liposome magnetic particles (ELMP) and characterized their physicochemical properties before evaluating their enrichment efficiency for epithelial breast cancer cells. ELMP effectively enriched epithelial CTCs. The ROC curve area for CK19 alone was 0.889, whereas the combined CK19/hMAM assay reached 0.96, demonstrating superior alignment with clinical diagnoses. We propose hMAM as a novel biomarker for breast cancer CTC identification. The dual-marker approach significantly enhances both the specificity and sensitivity of CTC detection.

PMID 43050786
阅读全文 →
PubMedBladder cancer (Amsterdam, Netherlands)2026-11-18

Impact of diagnostic transurethral bladder tumour resection on the release of circulating tumour cells.

Verhaegh Gerald W GW, Kiemeney Lambert A LA, van Hoogstraten Lisa M C LMC, Groen Levi L et al.

To evaluate the impact of transurethral resection of the bladder tumour (TURBT) on the release of circulating tumour cells (CTCs) in patients suspected of having muscle-invasive bladder cancer (MIBC) and to assess metastasis in follow-up analysis. In this prospective pilot study for the BladParadigm trial, patients suspected of having MIBC were recruited and underwent TURBT for local staging. Peripheral blood samples were collected just before and immediately after TURBT. CTCs were enriched using the Parsortix® PR1 microfluidics system. Cytokeratin-positive CTCs were counted using fluorescence microscopy. Progression and survival were evaluated at 2 years since inclusion. Of 18 patients included, seven were diagnosed with NMIBC and eleven with MIBC. Of all MIBC patients, 1 patient was already CTC-positive before TURBT. Four other MIBC patients were CTC-positive only after TURBT, indicating a CTC rise after TURBT in 40% (4/10) of pre-TURBT CTC-negative MIBC cases. Two out of these four patients experienced progression within two years, of whom one deceased. Two out of six CTC-negative patients before and after TURBT also experienced progression. We demonstrate the feasibility of using label-free enrichment to capture and enumerate bladder cancer-derived CTCs. Our findings indicate that TURBT might lead to the spread of CTCs. Although this feasibility study lacks power, the detection of TURBT-associated CTCs suggests a need to study non-invasive alternatives for local staging of bladder cancer.

PMID 43048459
阅读全文 →
PubMedAnalytical chemistry2026-11-18

Interfacial Charge-Regulated DNA Nanonets Enable Polarity-Switching Photoelectrochemical Liquid Biopsy of Lung Adenocarcinoma Circu-lating Tumor Cells.

Jiang Ying Y, Wang Nanbo N, You Heng H, Xu Zhi Z et al.

Conventional clinical diagnostic of lung adenocarcinoma relies heavily on computed tomography imaging combined with tissue biopsyan invasive workflow that drastically limits patient compliance and impedes early screening and dynamic monitoring. Although circulating tumor cells (CTCs) enable minimally invasive disease tracking, their clinical detection is severely compromised by ultralow abundance and complex hematological interferences. Herein, we present a dye-induced signal-reversal photoelectrochemical (PEC) biosensor for sensitive and accurate CTC detection in raw whole blood. Specific CTC recognition triggers a Mg2+-dependent DNAzyme-cascaded amplification, yielding abundant single-stranded DNA that programmably assembles into an acriflavine-confined nanonet at the electrode interface. This engineered nano-biointerface alters charge-transfer kinetics, thus driving a distinct anodic-to-cathodic photocurrent transition to effectively eliminate background noise and improve signal reliability, enabling ultrasensitive CTC quantification across a broad linear range (10-105 cells·mL-1) and an ultralow detection limit (0.11 cell·mL-1), along with excellent selectivity, stability, and reproducibility. Notably, clinical validation of the proposed biosensor using whole blood samples from lung adenocarcinoma patients (n = 78) and healthy donors (n = 22) shows high diagnostic accuracy (area under the curve = 0.9129) and strong consistency with radiologic findings. This engineered PEC sensing platform offered a robust, minimally invasive liquid biopsy strategy for early lung adenocarcinoma screening, therapeutic response assessment, and longitudinal disease management in personalized medicine.

PMID 43046394
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多CTC-111